ATXI vs. ARAV, NBY, BPTS, ARDS, AGRX, CYCC, VRPX, CLVR, BPTSY, and PHIO
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Aravive (ARAV), NovaBay Pharmaceuticals (NBY), Biophytis (BPTS), Aridis Pharmaceuticals (ARDS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), Virpax Pharmaceuticals (VRPX), Clever Leaves (CLVR), Biophytis (BPTSY), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Aravive (NASDAQ:ARAV) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
35.8% of Aravive shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aravive presently has a consensus price target of $13.50, indicating a potential upside of 33,565.84%. Given Avenue Therapeutics' higher possible upside, analysts plainly believe Aravive is more favorable than Avenue Therapeutics.
Avenue Therapeutics received 43 more outperform votes than Aravive when rated by MarketBeat users. However, 62.28% of users gave Aravive an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote.
Avenue Therapeutics has lower revenue, but higher earnings than Aravive. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avenue Therapeutics had 14 more articles in the media than Aravive. MarketBeat recorded 14 mentions for Avenue Therapeutics and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 beat Avenue Therapeutics' score of 0.00 indicating that Avenue Therapeutics is being referred to more favorably in the news media.
Avenue Therapeutics has a net margin of 0.00% compared to Avenue Therapeutics' net margin of -569.65%.
Aravive has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.
Summary
Aravive beats Avenue Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
